|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-3.09/-3.15
|
企業價值
420.50M
|
資產負債 |
每股賬面淨值
8.60
|
現金流量 |
現金流量率
--
|
損益表 |
收益
50.00M
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/24 13:23 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |